Foghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate Update
Provided By GlobeNewswire
Last update: Nov 4, 2024
First patient dosed with first-in-class SMARCA2(BRM) selective inhibitor FHD-909 (LY4050784) in Phase 1 trial with primary target population in SMARCA4(BRG1) mutated NSCLC
